Elevated doses of chemotherapy may benefit younger lymphoma patients HemOncToday Researchers found that an intensive form of chemotherapy — when combined with the monoclonal antibody drug rituximab (Rituxan; Genentech/Idec Pharmaceuticals) — could reduce recurrence of the disease and increase survival rates among patients aged ... |
